Neurotech International Limited announced the expansion of its exclusive license with Dolce Cann Global Pty Ltd. to now include all neurological disorders, specifically - Autism, Epilepsy, ADHD, Alzheimer's disease, Huntington's disease, Multiple Sclerosis, Transverse Myelitis, Inflammatory Brain disease, Fibromyalgia, Chronic Fatigue, Migraine and any other disorder, disease or affliction affecting the human brain function. Latest clinical research demonstrates that inflammation, and more specifically neuroinflammation - is a well- recognised common feature in all neurological disorders1. Based on the scientific data generated to date, unlike CBD alone the NTI/Dolce full spectrum medicinal cannabis strains have powerful, neuro-modulatory, anti-inflammatory and neuro-regulatory mode of action. The activity of these strains is up to 80% more potent than CBD alone and can regulate the suppression of inflammation via the suppression of the Arginase 1 pathway and beta- tubulin regulation which is a vital protein in the management of several neurological diseases such as Alzheimer's disease, Huntington's disease and Multiple Sclerosis. The global market for neurology treatments is expected to grow to $39.4 billion by 20242. Rising prevalence of neurological diseases coupled with increasing awareness associated with the disease diagnosis in developing countries is assisting the market growth.